纤溶酶联合依达拉奉治疗进展性脑梗死的疗效观察(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 观察纤溶酶联合依达拉奉治疗进展性脑梗死的疗效。 方法 将80例进展性脑梗死患者随机分为试验组(40例)及对照组(40例)，两组均给与阿司匹林肠溶片、阿托伐他汀钙片治疗，试验组在此基础上给予纤溶酶联合依达拉奉注射液静脉滴注，14 d为1个疗程。 结果 试验组神经功能缺损评分在7、14 d时明显低于对照组(P < 0.05)。 结论 纤溶酶联合依达拉奉治疗进展性脑梗死疗效显著。
[关键词] 纤溶酶；依达拉奉；脑梗死；疗效观察
[中图分类号] R743 [文献标识码] A [文章编号] 1674-4721(2012)07(a)-0098-02
Study on the efficacy of fibrinogenase combined with edaravone on progressive cerebral infarction
ZHANG Ge
Department of Neurology, Luoyang Dongfang Hospital, the Third Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, China
[Abstract] Objective To observe the efficacy of fibrinogenase combined with edaravone on progressive cerebral infarction. Methods Eighty cases of progressive cerebral infarction patients were randomly divided into experimental group (40 cases) and control group (40 cases). Two groups were both given aspirin, atorvastatin calcium tablets, and experimental group was additionally given fibrinogenase injection combined with edaravone injection for 14 days. Results Neurological deficit score of experimental group at 7 days, 14 days was significantly lower than that of control group (P < 0.05). Conclusion The efficacy of fibrinogenase combined with edaravone on progressive cerebral infarction is remarkable.
[Key words] Fibrinogenase; Edaravone; Brain Infarction; Efficacy observation
超早期脑梗死可通过尿激酶等药物静脉溶栓[1]，而错过溶栓时间窗的患者，病情仍可能继续加重，即为进展性脑梗死。对于这类患者，临床尚无特别有效的治疗方法。纤溶酶有降解纤维蛋白、抗凝和抗血小板聚集等作用，依达拉奉通过抗自由基，共同阻止脑梗死进展。本科近年来采用纤溶酶联合依达拉奉注射液治疗进展性脑梗死，疗效显著，报道如下：
1 资料与方法
1.1 一般资料
所选80例患者，男46例，女34例，均符合中华医学会第四届全国脑血管病学术会议所制定的诊断标准[2]，均为2010年1月～2012年1月本院神经内科住院患者，经临床规范治疗，发病后72 h内局灶性神经功能缺损症状仍进行性加重者。同时，排除颅内出血、脑肿瘤、大面积脑梗死等，无严重内脏功能不全，近期无大手术、活动性出血，血常规、凝血功能检测正常。随机将其分为试验组和对照组。试验组40例，男22例，女18例，年龄45～75岁 ......
您现在查看是摘要介绍页，详见PDF附件(2175kb)。